All In Biotech

Drug Trial Radar · NCT02105610

Volatile Anesthetics to Reduce Mortality in Cardiac Surgery

Volatile Anesthetics to Reduce Mortality in Cardiac Surgery: A Multicentre Randomized Controlled Study

Last checked: Nov 19, 2026Latest source record: Apr 2, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 5,400 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

5,400

Actual

Start

Apr 14, 2014

Primary completion

Oct 2017

Study completion Sep 2018

Sponsor

Lead sponsor
Università Vita-Salute San RaffaeleAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 7, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

There is initial evidence that the choice of anesthesia can influence survival in the specific setting of coronary artery bypass grafting surgery (CABG). A recent international consensus conference included volatile agents among the few drugs/techniques/strategies that might reduce perioperative mortality in cardiac surgery and that should be further studied. Volatile anesthetics (desflurane, isoflurane and sevoflurane) have non-anesthetic pharmacological characteristics that confer cardiac protection when compared to Total IntraVenous Anesthesia (TIVA). Several randomized controlled studies were summarized in a meta-analysis that documented a reduction in perioperative cardiac troponin release and mortality in patients receiving volatile anesthetics when compared to patients receiving a TIVA. There are four published studies (Bignami et al. 2009) (De Hert et al. 2009) (Jackobsen et al. 2007) (Landoni et al. 2007) suggesting that these benefits can translate into a reduced mortality rate in patients receiving volatile agents. The level of evidence for these four studies is not high (one meta-regression, one underpowered randomized controlled study, one retrospective study and one meta-analysis of small randomized studies) and there is need for a large multicentre randomized controlled study to confirm these findings, as suggested by the international consensus conference on this topic published in 2011 (Landoni et al 2011). The purpose is to provide a large multicentre controlled randomized trial to demonstrate that volatile anesthetics can reduce 1 year mortality from 3% to 2% in patients undergoing CABG (either with or without cardiopulmonary bypass). The results of this study can support the use of volatile agents in all CABG procedures worldwide (more than 500.000 per year) with 2.500 lives saved per year (in the hypothesis that nowadays half the procedures are performed with a TIVA and that 1 year mortality can be reduced from 3% to 2% using volatile agents).

Conditions

  • Aortocoronary Bypass
  • Cardiac Surgery
  • Coronary Artery Bypass Grafting

Interventions

  • desflurane, isoflurane, sevofluraneDrug

  • total intravenous anestheticsDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. mortalityTime frame: 1 year

Locations

36 sites in 13 countries. Site status is shown where the registry gives one.

  • Mohammed Bin Khalifa Bin Sulman Al-Khalifa Cardiac Center - Bahrain

    Bahrein, Bahrain

  • Dante Pazzanese Institute of Cardiology

    São Paulo, Brazil

  • Hospital das Clínicas da Faculdade de Medicina da USP - Istituto do Coracao

    São Paulo, Barazil, Brazil

  • Heart Center Pontica

    Burgas, Bulgaria

  • Beijing Anzhen Hospital, Capital Medical University

    Beijing, China

  • The Second Xiangya Hospital of Central South University

    Changsha, China

  • Wuhan Asia Heart Hospital

    Hubei, China

  • 1st Affiliated Hospital of Fourth Military University

    Xi'an, China

  • University Hospital Dubrava

    Dubrava, Croatia

  • General University Hospital, Charles University

    Prague, Czech Republic, Czechia

  • Institute for Clinical and Experimental Medicine

    Prague, Czech Republic, Czechia

  • Faculty of Medicine - Zagazig University

    Zagazig, Egypt

  • Mansoura University hospitals

    Egypt, Egypt, Egypt

  • Policlinico San Orsola-Malpighi

    Bologna, Italy

  • Spedali Civili

    Brescia, Italy

  • Policlinico Universitario Magna Graecia

    Catanzaro, Italy

  • Ospedale San Raffaele di Milano, Italy

    Milan, Italy

  • Humanitas

    Milan, Italy

  • Azienda Ospedaliera di Padova

    Padova, Italy

  • Azienda Ospedaliera San Camillo-Forlanini

    Roma, Italy

  • Policlinico Universitario Campus Biomedico

    Roma, Italy

  • AOU Città della Salute e della Scienza

    Torino, Italy

  • Hospital Pulau Pinang

    George Town, Malaysia, Malaysia

  • Hospital Serdang

    Lumpur, Malaysia, Malaysia

  • University Malaya Medical Centre

    Lumpur, Malaysia, Malaysia

  • Sarawak General Hospital

    Sarawak, Malaysia, Malaysia

  • Hospital Santa Maria

    Lisbon, Portugal

  • Federal Centre for Cardiac Surgery

    Astrakhan, Russia

  • Scientific Research Institute for Complex Issues of Cardiovascular Disease

    Kemerovo, Russia

  • Moscow Clinical Regional Research Institute

    Moscow, Russia

  • Negovskiy Reanimatology Research Institute

    Moscow, Russia

  • State Research Institute of Circulation Pathology

    Novosibirsk, Russia

  • Federal Almazov Medical Research Centre

    Saint Petersburg, Russia

  • Ural Institute of Cardiology

    Yekaterinburg, Russia

  • King Abdullah Medical City - KAMC

    Mecca, Saudi Arabia

  • Institute of Cardiovascular Diseases "Dedinje"

    Belgrade, Serbia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.